Zobrazeno 1 - 10
of 31
pro vyhledávání: '"R V, Smalley"'
Autor:
Lesley A. Stewart, S. B. Kaye, S. Pecorelli, N. Colombo, C. Mangioni, R. V. Smalley, B. Y. Yeap, D. W. Wilbur, R. C. Leonard, M. F. Brady, E. Wiltshaw, P. F. Conte, S. Marsoni, J. F.G. Sturgeon, M. H.N. Tattersall, C. Gennatas, C. Trope, A. Athanazziou, D. Guthrie, D. Crowther, D. R. Bell, A. H. Laing, M. Gore, J. B. Vermorken, C. Lewis, E. Gilbey, Giorgio Bolis, H. Bruckner, P. Adnitt, M. K.B. Parmar, M. Tomirotti, H. Meerpohl, H. S. Brodovsky, W. Sauerbrei, J. Pater, R. Canetta, W.W. ten Bokkel Huinink, D. V. Skarlos, H. J. Solomon, M. J. Webb, J. T. Wharton, F. Landoni, P. Y. Liu, M. M. Turbow, J. H. Edmonson, D. S. Alberts, C. J. Cohen, K. Aabo, W. Torri, V. Barley, M. Adams, M. Buyse, C. J. Williams, M. Presti, V. Chylak, U. Bianchi, G. A. Omura
Publikováno v:
Scopus-Elsevier
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2151ac8be4c1ee28ab74e9cc655baa87
https://doi.org/10.1038/bjc.1998.710
https://doi.org/10.1038/bjc.1998.710
Autor:
S, Haase-Statz, R V, Smalley
Publikováno v:
Oncology (Williston Park, N.Y.). 13(8)
Recombinant interferon-alfa (Intron A, Roferon-A) has been under investigation as a therapeutic agent for non-Hodgkin's lymphoma (NHL) for 25 years. It has antitumor efficacy in a number of histologic subtypes but has not been accepted as a clinicall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5f4bc6895ea6f240852626137ca2d990
https://pubmed.ncbi.nlm.nih.gov/10499247
https://pubmed.ncbi.nlm.nih.gov/10499247
Autor:
R V, Smalley, S A, Anderson, R L, Tuttle, J, Connors, L M, Thurmond, A, Huang, K, Castle, C, Magers, J K, Whisnant
Publikováno v:
Blood. 78(12)
One hundred thirty-eight patients with hairy cell leukemia were randomized to receive either a dose of 2.0 megaunits (MU)/m2 or a 10-fold lower dose of 0.2 MU/m2 of a highly purified natural alpha-interferon, administered daily for 28 days followed b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f26c049352bf989941f4126a23af93f
https://pubmed.ncbi.nlm.nih.gov/1742480
https://pubmed.ncbi.nlm.nih.gov/1742480
Publikováno v:
Advances in experimental medicine and biology. 294
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ad1bc2c9f7669afe3046b504566b4e5e
https://pubmed.ncbi.nlm.nih.gov/1772089
https://pubmed.ncbi.nlm.nih.gov/1772089
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9781468459548
Antiproliferative effects of interferon (IFN)-γ in vitro on some tumor cells (de 1a Maza and Peterson, 1988; Ozaki et al., 1988a; Takikawa et al., 1988), Chlamvdia psittaci (Byrne et al., 1986) and Toxoplasma gondii (Pfefferkorn, 1984) are mediated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e13cddf27f7c38197bdf195b54146e1
https://doi.org/10.1007/978-1-4684-5952-4_64
https://doi.org/10.1007/978-1-4684-5952-4_64
Publikováno v:
Seminars in oncology. 17(6 Suppl 9)
Megestrol acetate was administered as first-line therapy to 152 patients with advanced breast cancer. Forty-three of 136 evaluable patients (32%) obtained an objective response (95% confidence interval, 24% to 40%). Toxicity was minimal, with only 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e3944ccc355b93cdab56abca771e0818
https://pubmed.ncbi.nlm.nih.gov/2259926
https://pubmed.ncbi.nlm.nih.gov/2259926
Publikováno v:
Journal of interferon research. 10(4)
2',5'-Oligoadenylate (2-5A) synthetase is an intracellular enzyme induced during viral diseases and after clinical administration of interferons (IFN). Because monocytes and T and B lymphocytes in peripheral blood are targets of viral infection, we c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::376cf8e5d477c9382fc693c019d7533b
https://pubmed.ncbi.nlm.nih.gov/2121851
https://pubmed.ncbi.nlm.nih.gov/2121851
Autor:
John T. Carpenter, Enrique Velez-Garcia, Charles L. Vogel, M Raney, Stephen Krauss, M Stagg, E Fishkin, S Raab, Melvin R. Moore, R V Smalley
Publikováno v:
Journal of Clinical Oncology. 2:643-651
Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa6f7c35008ab248cd959e03f7cdd86
https://doi.org/10.1200/jco.1984.2.6.643
https://doi.org/10.1200/jco.1984.2.6.643
Autor:
R. V. Smalley
Publikováno v:
Archives of Internal Medicine. 120:599-601
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b148cc49fb3af8ad7aec162249fb08b
https://doi.org/10.1001/archinte.120.5.599
https://doi.org/10.1001/archinte.120.5.599
Autor:
D K, Mayer, R V, Smalley
Publikováno v:
Oncology nursing forum. 10(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e1599bb6872a4d81974d940cbb293a61
https://pubmed.ncbi.nlm.nih.gov/6195644
https://pubmed.ncbi.nlm.nih.gov/6195644